CoChat
Sign Up
Cited by 83Cytomegalovirus and herpesvirus researchInfluenza Virus Research StudiesImmune responses and vaccinations

Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities

Open access
den Elzen, Wendy P.J., Vossen, Ann C.M.T., Cools, Herman J.M., Westendorp, Rudi G.J., Kroes, Aloys C.M., Gussekloo, Jacobijn·2011·Vaccine
DOI 10.1016/j.vaccine.2011.03.086
Open this paper in CoChat — free accountOpen PDF

Abstract

Ample evidence suggests that infection with cytomegalovirus (CMV) leads to accelerated aging of the immune system and may contribute to poor responsiveness to influenza vaccination in older persons. The objective of this study was to investigate whether CMV infection, acquired earlier in life, affects the response to influenza vaccination in a randomized controlled trial among older persons in long-term care facilities. During the 1997-1998 influenza season, 731 residents (median age 83 [interquartile range 78-88], 75.4% female) in 14 long-term care facilities in the Netherlands were randomly assigned to receive 15 or 30 μg of inactivated influenza vaccine, followed by a 15 μg booster vaccine or a placebo vaccine at day 84. Blood samples were collected at day 0, day 25, day 84 and day 109. Seroresponses to influenza vaccination were measured by hemagglutination-inhibition tests to the A/H3N2 strain at all time points. Subsequently, baseline levels of IgG anti-CMV antibodies were measured using an automated chemiluminescent microparticle immunoassay. Participants with CMV antibody level≥6 AU/mL were considered to harbor CMV infection. At baseline, no differences in pre-vaccination geometric mean antibody titers (GMT) were observed between participants with (n=571, 78.1%) or without CMV infection (n=160, 21.9%). During follow-up, participants with and without CMV infection had similar responses to influenza vaccination as measured with changes in GMT (linear mixed model, adjusted for gender, age, pre-vaccination GMT and vaccination strategy, p=0.46). Analogously, no association was found between CMV infection and a more than 4-fold increase in antibody titer (Generalized Estimating Equations, adjusted OR 1.14 [95%CI 0.80;1.64]) or an antibody titer≥40 (adjusted OR 1.24 [95%CI 0.86;1.80]). In conclusion, CMV infection did not explain poor responsiveness to influenza vaccination in residents of long-term care facilities.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2011.03.086

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some studies have shown no effect of CMV on vaccine responses in the elderly.

    “For example, some studies have shown no effect of CMV on vaccine responses in the elderly (den Elzen et al. 2011; O’Connor et al. 2014; Wald et al. 2013) and other studies have even reported vaccine-boosting effects of CMV in young individuals (Furman et al. 2015).”

    From Is immunosenescence influenced by our lifetime “dose” of exercise? (2016) · cites this paper as den Elzen et al. 2011

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
den Elzen, W. P. J., Vossen, A. C. M. T., Cools, H. J. M., Westendorp, R. G. J., Kroes, A. C. M., & Gussekloo, J.
Affiliations
Leiden University Medical Center (NL)
ORCID
Venue
Vaccine
Publisher
Elsevier BV
Published
2011-06
Volume
29
Issue
29-30
Pages
4869-4874
ISSN
0264-410X (ISSN-L)
DOI
10.1016/j.vaccine.2011.03.086
OpenAlex
W2089074316
Cited by
83
References
25
Citations by year
2025: 3 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 7 · 2017: 8 · 2016: 9 · 2015: 9 · 2014: 2 · 2013: 7 · 2012: 8
FWCI
4.56
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
  • Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords
cytomegalovirus infection, influenza vaccination, vaccine response, long-term care residents, older adults, seroconversion, anti-CMV antibodies, hemagglutination inhibition antibodies, H3N2, booster vaccination, immunosenescence
MeSH terms
Aged, Aged, 80 and over, Antibodies, Viral, Cytomegalovirus Infections, Cytomegalovirus, Female, Humans, Immunoglobulin G, Immunization, Secondary, Immunoassay, Influenza, Human, Influenza Vaccines, Long-Term Care, Male, Netherlands, Placebos, Vaccination, Vaccines, Inactivated

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review